prednisolone and Neoplasm Metastasis
prednisolone has been researched along with Neoplasm Metastasis in 111 studies
Prednisolone: A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states.
prednisolone : A glucocorticoid that is prednisone in which the oxo group at position 11 has been reduced to the corresponding beta-hydroxy group. It is a drug metabolite of prednisone.
Neoplasm Metastasis: The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Research Excerpts
Excerpt | Relevance | Reference |
---|---|---|
"The addition of radium-223 to abiraterone acetate plus prednisone or prednisolone did not improve symptomatic skeletal event-free survival in patients with castration-resistant prostate cancer and bone metastases, and was associated with an increased frequency of bone fractures compared with placebo." | 9.30 | Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial. ( Boegemann, M; Heidenreich, A; Higano, C; Kakehi, Y; Karyakin, O; Kimura, G; Krissel, H; Matsubara, N; Matveev, V; Miller, K; Nahas, WC; Ng, QS; Nolè, F; Parker, C; Piulats, JM; Rosenbaum, E; Saad, F; Shen, J; Smith, M; Teufel, M; Tombal, B; Wagner, V; Zhang, A; Zucca, LE, 2019) |
"To determine the effect of prednisolone on severe hypercalcaemia in women with metastatic breast cancer, 30 patients with serum ionized calcium above 1." | 9.07 | Prednisolone in the treatment of severe malignant hypercalcaemia in metastatic breast cancer: a randomized study. ( Ejlertsen, B; Holmegaard, SN; Krarup-Hansen, A; Kristensen, B; Mouridsen, H; Transbøl, I, 1992) |
"Thirty-eight patients with advanced breast cancer were treated with the 'VEMFAH' multiple-drug combination chemotherapy, consisting of vincristine (V), cyclophosphamide (Endoxan; E), methotrexate (M), 5-fluorouracil (F), adriamycin (A), and prednisolone (H)." | 9.05 | The effects of multiple combination chemotherapy with vincristine, cyclophosphamide (Endoxan), methotrexate, 5-fluorouracil, adriamycin and prednisolone (VEMFAH) for advanced breast cancer. ( Hoshino, A; Ito, Y; Kamiya, O; Kinoshita, T; Kojima, T; Nagata, K; Ohara, K; Sato, H; Sugiura, I; Yamada, M, 1985) |
"Fifty patients with metastatic breast cancer were treated with a combination of vincristine, Adriamycin and prednisolone (VAP) at four weekly intervals." | 7.66 | Combination chemotherapy of metastatic breast cancer with vincristine adriamycin and prednisolone. ( Baker, JW; Dady, PJ; Ford, HT; Gazet, JC; McKinna, JA; Nash, AG; Powles, TJ; Russell, JA, 1978) |
"Sorafenib is an orally administered active multikinase inhibitor for metastatic renal cell carcinoma that is now considered a standard agent." | 5.39 | Stevens-Johnson syndrome induced by sorafenib for metastatic renal cell carcinoma. ( Amoh, Y; Fujita, T; Ikeda, M; Iwamura, M; Matsumoto, K; Mii, S, 2013) |
"Radiation-induced gastritis is an infrequent cause of gastrointestinal bleeding." | 5.38 | Treatment of radiation-induced hemorrhagic gastritis with prednisolone: a case report. ( Chen, Y; Ren, ZG; Wang, Y; Wang, YH; Xie, XY; Zhang, L, 2012) |
"The addition of radium-223 to abiraterone acetate plus prednisone or prednisolone did not improve symptomatic skeletal event-free survival in patients with castration-resistant prostate cancer and bone metastases, and was associated with an increased frequency of bone fractures compared with placebo." | 5.30 | Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial. ( Boegemann, M; Heidenreich, A; Higano, C; Kakehi, Y; Karyakin, O; Kimura, G; Krissel, H; Matsubara, N; Matveev, V; Miller, K; Nahas, WC; Ng, QS; Nolè, F; Parker, C; Piulats, JM; Rosenbaum, E; Saad, F; Shen, J; Smith, M; Teufel, M; Tombal, B; Wagner, V; Zhang, A; Zucca, LE, 2019) |
"To determine the effect of prednisolone on severe hypercalcaemia in women with metastatic breast cancer, 30 patients with serum ionized calcium above 1." | 5.07 | Prednisolone in the treatment of severe malignant hypercalcaemia in metastatic breast cancer: a randomized study. ( Ejlertsen, B; Holmegaard, SN; Krarup-Hansen, A; Kristensen, B; Mouridsen, H; Transbøl, I, 1992) |
"Thirty-eight patients with advanced breast cancer were treated with the 'VEMFAH' multiple-drug combination chemotherapy, consisting of vincristine (V), cyclophosphamide (Endoxan; E), methotrexate (M), 5-fluorouracil (F), adriamycin (A), and prednisolone (H)." | 5.05 | The effects of multiple combination chemotherapy with vincristine, cyclophosphamide (Endoxan), methotrexate, 5-fluorouracil, adriamycin and prednisolone (VEMFAH) for advanced breast cancer. ( Hoshino, A; Ito, Y; Kamiya, O; Kinoshita, T; Kojima, T; Nagata, K; Ohara, K; Sato, H; Sugiura, I; Yamada, M, 1985) |
"Ninety-one assessable elderly women (greater than 65 years) with advanced breast cancer were treated with prednisolone 15 mg (or cortisone 75 mg) daily after primary endocrine treatment (estrogens, androgens or tamoxifen)." | 3.66 | Corticosteroids for elderly patients with breast cancer. ( Hayward, JL; Knight, RK; Minton, MJ; Rubens, RD, 1981) |
"Fifty patients with metastatic breast cancer were treated with a combination of vincristine, Adriamycin and prednisolone (VAP) at four weekly intervals." | 3.66 | Combination chemotherapy of metastatic breast cancer with vincristine adriamycin and prednisolone. ( Baker, JW; Dady, PJ; Ford, HT; Gazet, JC; McKinna, JA; Nash, AG; Powles, TJ; Russell, JA, 1978) |
" Most common adverse event was nasopharyngitis (15/50 patients, 30." | 3.01 | Efficacy and safety of abiraterone acetate plus prednisolone in patients with early metastatic castration-resistant prostate cancer who failed first-line androgen-deprivation therapy: a single-arm, phase 4 study. ( Arai, G; Furukawa, J; Iinuma, M; Kamiya, N; Kikukawa, H; Kobayashi, H; Kobayashi, K; Maniwa, A; Mikami, K; Nakashima, T; Nakatsu, H; Nasu, Y; Okuno, N; Satoh, T; Tanabe, K; Uemura, H, 2021) |
" Ipatasertib bioavailability and M1 formation increased after multiple dosing, resulting in an increase in exposure beyond that expected from accumulation alone." | 3.01 | Population Pharmacokinetics of Ipatasertib and Its Metabolite in Cancer Patients. ( Chanu, P; Kotani, N; Sane, R; Wade, JR; Wang, N; Wilkins, J; Winkler, J; Yoshida, K, 2021) |
" Adverse events (AEs) possibly related to cabazitaxel occurred in 143 (93." | 2.79 | Cabazitaxel for metastatic castration-resistant prostate cancer: safety data from the Spanish expanded access program. ( Antón Aparicio, LM; Batista, N; Castellano, D; Esteban, E; Germà, JR; Luque, R; Maroto, P; Méndez-Vidal, MJ; Pérez-Valderrama, B; Sánchez-Hernández, A, 2014) |
"Abiraterone acetate has been approved in >70 countries for chemotherapy-naïve metastatic castration-resistant prostate cancer patients." | 2.79 | A phase 2 trial of abiraterone acetate in Japanese men with metastatic castration-resistant prostate cancer and without prior chemotherapy (JPN-201 study). ( Akaza, H; Hashine, K; Imanaka, K; Matsubara, N; Nishiyama, T; Ozono, S; Satoh, T; Suzuki, H; Uemura, H, 2014) |
"Seventy patients with breast cancer (stage IIIb--IV) were randomized by an "envelope" method into 2 groups, each including 35 persons." | 2.64 | [Combined drug treatment of far-advanced forms of breast cancer]. ( Borisov, AI, 1978) |
"Abiraterone acetate has recently demonstrated a significant improvement in survival when compared to placebo in patients with docetaxel-treated mCRPC." | 2.47 | Role of second-line systemic treatment post-docetaxel in metastatic castrate resistant prostate cancer- current strategies and future directions. ( Alhasso, A; Ansari, A; Ansari, J; Glaholm, J; Hussain, SA; Mahmood, R, 2011) |
"Advanced prostate cancer is typically sensitive to androgen-deprivation therapy, but invariably progresses to the castration-resistant state." | 2.47 | Novel therapeutic strategies for metastatic prostate cancer in the post-docetaxel setting. ( de Bono, JS; Massard, C; Michels, RM; Sartor, O, 2011) |
"Treatment of hormone-refractory prostate cancer is palliative, and surgery and radiotherapy are used for the relief of lower urinary tract symptoms and localized painful bony metastases." | 2.43 | The changing pattern of management for hormone-refractory, metastatic prostate cancer. ( Bloomfield, D; James, ND; Luscombe, C, 2006) |
"Liver metastasis emerged two months after surgical resection, and the histology of the proliferating spindle cells sampled by a fine-needle biopsy was similar to that of the rectal tissue." | 1.56 | Aggressive Inflammatory Myofibroblastic Tumor without Anaplastic Lymphoma Kinase Gene Rearrangement in the Rectum with Liver Metastasis. ( Fukuda, S; Hiroshima, Y; Iijima, K; Koizumi, S; Matsuhashi, T; Nanjo, H; Ohba, R; Shimodaira, Y; Sugawara, K; Suzuki, Y; Watanabe, N, 2020) |
"Cabazitaxel/prednisone has been shown to prolong survival versus mitoxantrone/prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or after docetaxel." | 1.40 | Safety of cabazitaxel in senior adults with metastatic castration-resistant prostate cancer: results of the European compassionate-use programme. ( Bracarda, S; Climent, MA; Fossa, S; Heidenreich, A; Hitier, S; Mason, M; Ozen, H; Papandreou, C; Sengelov, L; Van Oort, I, 2014) |
"Sorafenib is an orally administered active multikinase inhibitor for metastatic renal cell carcinoma that is now considered a standard agent." | 1.39 | Stevens-Johnson syndrome induced by sorafenib for metastatic renal cell carcinoma. ( Amoh, Y; Fujita, T; Ikeda, M; Iwamura, M; Matsumoto, K; Mii, S, 2013) |
"Radiation-induced gastritis is an infrequent cause of gastrointestinal bleeding." | 1.38 | Treatment of radiation-induced hemorrhagic gastritis with prednisolone: a case report. ( Chen, Y; Ren, ZG; Wang, Y; Wang, YH; Xie, XY; Zhang, L, 2012) |
" Treatment continued without obvious side effects, and PDL dosage was tapered to 10 mg/day." | 1.36 | [Complete response achieved in a case of gastric gastrointestinal stromal tumor by administration of imatinib mesilate with concurrent relatively high-dose steroid therapy to control side effects]. ( Kishimoto, H; Nakamura, M; Otagiri, N; Sasahara, K; Tauchi, K; Tsukada, Y; Yoshifuku, S, 2010) |
" Both therapeutic agents were suspected as a possible cause of this adverse event." | 1.34 | Severe lung and skin toxicity during treatment with gemcitabine and erlotinib for metastatic pancreatic cancer. ( Boeck, S; Hausmann, A; Heinemann, V; Reibke, R; Schulz, C, 2007) |
" The bioavailability is nearly 100% after oral application, and the main metabolites are 4-hydroxytrofosfamide, and 4-hydroxyifosfamide." | 1.32 | Hypersensitivity pneumonitis associated with the use of trofosfamide. ( Hartmann, JT; Kanz, L; Kopp, HG, 2004) |
"A case of osteogenic sarcoma of the maxilla is described." | 1.26 | Chemotherapy in the treatment of osteogenic sarcoma of the maxilla (case report). ( Nakajima, T; Yokobayashi, T, 1978) |
"The apparent risk of early CNS disease suggests that prophylactic CNS therapy should be given early in the treatment of acute non-myelogenous leukaemia." | 1.26 | Early central nervous system involvement in adults with acute non-myelogenous leukaemia. ( Beard, ME; Brearley, RL; Brown, L; Crowther, D; Lister, TA; Paxton, A; Whitehouse, JM; Wrigley, PF, 1977) |
"At autopsy a large single metastasis was found in the right atrium and tumour emboli in the pulmonary artery." | 1.26 | Rapid platelet consumption in a case of metastatic osteogenic sarcoma of the breast. ( Johansson, S; Kutti, J; Olsson, LB, 1978) |
"Estramustine has been shown previously to be an effective drug in the treatment of metastatic prostatic cancer, demonstrating significant objective and subjective responses in long-term non-randomized trials and in other randomized trials." | 1.26 | The use of estramustine and prednimustine versus prednimustine alone in advanced metastatic prostatic cancer patients who have received prior irradiation. ( Chu, TM; Gaeta, JF; Gibbons, RP; Johnson, DE; Loening, SA; Murphy, GP; Prout, GR; Saroff, J; Schmidt, JD; Scott, WW; Slack, N; Soloway, MS; Wajsman, Z, 1979) |
Research
Studies (111)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 68 (61.26) | 18.7374 |
1990's | 4 (3.60) | 18.2507 |
2000's | 9 (8.11) | 29.6817 |
2010's | 25 (22.52) | 24.3611 |
2020's | 5 (4.50) | 2.80 |
Authors
Authors | Studies |
---|---|
George, DJ | 1 |
Shimodaira, Y | 1 |
Sugawara, K | 1 |
Fukuda, S | 1 |
Suzuki, Y | 1 |
Watanabe, N | 1 |
Koizumi, S | 1 |
Ohba, R | 1 |
Hiroshima, Y | 1 |
Matsuhashi, T | 1 |
Nanjo, H | 1 |
Iijima, K | 1 |
Yoshizawa, T | 1 |
Yamaguchi, K | 1 |
Kawata, N | 1 |
Ryuzaki, H | 1 |
Ogawa, M | 1 |
Obinata, D | 1 |
Mochida, J | 1 |
Takahashi, S | 1 |
Kobayashi, K | 1 |
Okuno, N | 1 |
Arai, G | 1 |
Nakatsu, H | 1 |
Maniwa, A | 1 |
Kamiya, N | 1 |
Satoh, T | 3 |
Kikukawa, H | 1 |
Nasu, Y | 1 |
Uemura, H | 4 |
Nakashima, T | 1 |
Mikami, K | 1 |
Iinuma, M | 1 |
Tanabe, K | 2 |
Furukawa, J | 1 |
Kobayashi, H | 1 |
Crabb, SJ | 1 |
Griffiths, G | 1 |
Marwood, E | 1 |
Dunkley, D | 1 |
Downs, N | 1 |
Martin, K | 1 |
Light, M | 1 |
Northey, J | 1 |
Wilding, S | 1 |
Whitehead, A | 1 |
Shaw, E | 1 |
Birtle, AJ | 2 |
Bahl, A | 1 |
Elliott, T | 1 |
Westbury, C | 1 |
Sundar, S | 1 |
Robinson, A | 2 |
Jagdev, S | 1 |
Kumar, S | 1 |
Rooney, C | 1 |
Salinas-Souza, C | 1 |
Stephens, C | 1 |
Khoo, V | 1 |
Jones, RJ | 3 |
Yoshida, K | 1 |
Wilkins, J | 1 |
Winkler, J | 1 |
Wade, JR | 1 |
Kotani, N | 1 |
Wang, N | 1 |
Sane, R | 1 |
Chanu, P | 1 |
Fizazi, K | 1 |
Tran, N | 1 |
Fein, L | 1 |
Matsubara, N | 3 |
Rodriguez-Antolin, A | 1 |
Alekseev, BY | 1 |
Özgüroğlu, M | 1 |
Ye, D | 1 |
Feyerabend, S | 1 |
Protheroe, A | 2 |
De Porre, P | 1 |
Kheoh, T | 1 |
Park, YC | 1 |
Todd, MB | 1 |
Chi, KN | 1 |
James, ND | 2 |
de Bono, JS | 2 |
Spears, MR | 1 |
Clarke, NW | 1 |
Mason, MD | 1 |
Dearnaley, DP | 1 |
Ritchie, AWS | 1 |
Amos, CL | 1 |
Gilson, C | 1 |
Matheson, D | 1 |
Millman, R | 1 |
Attard, G | 1 |
Chowdhury, S | 1 |
Cross, WR | 1 |
Gillessen, S | 1 |
Parker, CC | 1 |
Russell, JM | 2 |
Berthold, DR | 1 |
Brawley, C | 1 |
Adab, F | 1 |
Aung, S | 1 |
Bowen, J | 1 |
Brock, S | 1 |
Chakraborti, P | 1 |
Ferguson, C | 1 |
Gale, J | 1 |
Gray, E | 1 |
Hingorani, M | 1 |
Hoskin, PJ | 1 |
Lester, JF | 1 |
Malik, ZI | 1 |
McKinna, F | 1 |
McPhail, N | 1 |
Money-Kyrle, J | 1 |
O'Sullivan, J | 1 |
Parikh, O | 1 |
Srihari, NN | 1 |
Thomas, C | 1 |
Wagstaff, J | 2 |
Wylie, J | 1 |
Zarkar, A | 1 |
Parmar, MKB | 1 |
Sydes, MR | 1 |
Struss, WJ | 1 |
Black, PC | 1 |
Rulach, RJ | 1 |
McKay, S | 1 |
Neilson, S | 1 |
White, L | 1 |
Wallace, J | 1 |
Carruthers, R | 1 |
Lamb, C | 1 |
Cascales, A | 1 |
Marashi, H | 1 |
Glen, H | 1 |
Venugopal, B | 1 |
Sadoyze, A | 1 |
Sidek, N | 1 |
Alhasso, A | 2 |
Dodds, D | 1 |
Laskey, J | 1 |
MacLeod, N | 1 |
Biró, K | 1 |
Budai, B | 1 |
Szőnyi, M | 1 |
Küronya, Z | 1 |
Gyergyay, F | 1 |
Nagyiványi, K | 1 |
Géczi, L | 1 |
Nühnen, VP | 1 |
Schön, MP | 1 |
Mössner, R | 1 |
Adler, NR | 1 |
Murray, WK | 1 |
Brady, B | 1 |
McCormack, C | 1 |
Pan, Y | 1 |
Smith, M | 1 |
Parker, C | 1 |
Saad, F | 1 |
Miller, K | 1 |
Tombal, B | 1 |
Ng, QS | 1 |
Boegemann, M | 1 |
Matveev, V | 1 |
Piulats, JM | 1 |
Zucca, LE | 1 |
Karyakin, O | 1 |
Kimura, G | 1 |
Nahas, WC | 1 |
Nolè, F | 1 |
Rosenbaum, E | 1 |
Heidenreich, A | 2 |
Kakehi, Y | 2 |
Zhang, A | 1 |
Krissel, H | 1 |
Teufel, M | 1 |
Shen, J | 1 |
Wagner, V | 1 |
Higano, C | 1 |
Ikeda, M | 1 |
Fujita, T | 1 |
Amoh, Y | 1 |
Mii, S | 1 |
Matsumoto, K | 1 |
Iwamura, M | 1 |
Bracarda, S | 1 |
Mason, M | 1 |
Ozen, H | 1 |
Sengelov, L | 1 |
Van Oort, I | 1 |
Papandreou, C | 1 |
Fossa, S | 1 |
Hitier, S | 1 |
Climent, MA | 1 |
Castellano, D | 1 |
Antón Aparicio, LM | 1 |
Esteban, E | 1 |
Sánchez-Hernández, A | 1 |
Germà, JR | 1 |
Batista, N | 1 |
Maroto, P | 1 |
Pérez-Valderrama, B | 1 |
Luque, R | 1 |
Méndez-Vidal, MJ | 1 |
Lee, JL | 1 |
Park, SH | 1 |
Koh, SJ | 1 |
Lee, SH | 1 |
Kim, YJ | 1 |
Choi, YJ | 1 |
Lee, J | 1 |
Lim, HY | 1 |
Suzuki, H | 1 |
Nishiyama, T | 2 |
Hashine, K | 2 |
Imanaka, K | 2 |
Ozono, S | 3 |
Akaza, H | 3 |
Terai, A | 1 |
Yokomizo, A | 2 |
Nakatani, T | 1 |
Moriceau, G | 1 |
Guillot, A | 1 |
Pacaut, C | 1 |
Méry, B | 1 |
Falk, AT | 1 |
Trone, JC | 1 |
Collard, O | 1 |
De Laroche, G | 1 |
Fournel, P | 1 |
Merrouche, Y | 1 |
Magné, N | 1 |
Shiota, M | 1 |
Takeuchi, A | 1 |
Kiyoshima, K | 1 |
Inokuchi, J | 1 |
Tatsugami, K | 1 |
Shiga, KI | 1 |
Koga, H | 1 |
Yamaguchi, A | 1 |
Naito, S | 1 |
Eto, M | 1 |
Okamoto, K | 1 |
Ichinose, M | 1 |
Rassy, EE | 1 |
Assi, T | 1 |
Rizkallah, J | 1 |
Kattan, J | 1 |
Rice, CM | 1 |
Beric, V | 1 |
Love, S | 1 |
Scolding, NJ | 1 |
Tsukada, Y | 1 |
Tauchi, K | 1 |
Nakamura, M | 1 |
Kishimoto, H | 1 |
Yoshifuku, S | 1 |
Otagiri, N | 1 |
Sasahara, K | 1 |
Ansari, J | 1 |
Hussain, SA | 1 |
Mahmood, R | 1 |
Ansari, A | 1 |
Glaholm, J | 1 |
Sartor, O | 1 |
Michels, RM | 1 |
Massard, C | 1 |
Nishimura, K | 1 |
Nonomura, N | 1 |
Kanayama, HO | 1 |
Miura, T | 1 |
Miki, T | 1 |
Arai, Y | 1 |
Ogawa, O | 1 |
Fujita, R | 1 |
Nonomura, K | 1 |
Mizokami, A | 1 |
Hoshi, S | 1 |
Zhang, L | 1 |
Xie, XY | 1 |
Wang, Y | 1 |
Wang, YH | 1 |
Chen, Y | 1 |
Ren, ZG | 1 |
Başpinar, O | 1 |
Uçar, C | 1 |
Baysal, T | 1 |
Oran, B | 1 |
Karaaslan, S | 1 |
ROBSON, NL | 1 |
SCHMIDT, E | 1 |
SCHMIDT, FW | 1 |
OYAMA, T | 1 |
IRVINE, WT | 1 |
FRECKMAN, HA | 2 |
FRY, HL | 1 |
MENDEZ, FL | 1 |
MAURER, ER | 1 |
JAMIESON, WJ | 1 |
RUDERMAN, NB | 1 |
HALL, TC | 1 |
MANNHEIMER, IH | 1 |
Kopp, HG | 1 |
Kanz, L | 1 |
Hartmann, JT | 1 |
Miyoshi, I | 1 |
Saito, T | 1 |
Bandobashi, K | 1 |
Ohtsuki, Y | 1 |
Taguchi, H | 1 |
Bloomfield, D | 1 |
Luscombe, C | 1 |
Collins, R | 1 |
Trowman, R | 1 |
Norman, G | 1 |
Light, K | 1 |
Birtle, A | 1 |
Fenwick, E | 1 |
Palmer, S | 1 |
Riemsma, R | 1 |
Boeck, S | 1 |
Hausmann, A | 1 |
Reibke, R | 1 |
Schulz, C | 1 |
Heinemann, V | 1 |
Valencia-Parparcén, J | 1 |
Candia-Candia, E | 1 |
Kaltofen, G | 1 |
Bramwell, VH | 1 |
Howell, A | 1 |
Scarffe, H | 1 |
Crowther, D | 3 |
Sellwood, RA | 1 |
Andersson, L | 1 |
Edsmyr, F | 1 |
Esposti, PL | 1 |
Hedlund, PO | 1 |
Rönström, L | 1 |
Beckley, S | 1 |
Wajsman, LZ | 1 |
Slack, NH | 1 |
Murphy, GP | 2 |
Thatcher, N | 1 |
Wilkinson, P | 1 |
Palmer, M | 1 |
Dymarskiĭ, LIu | 1 |
Aleksandrova, GI | 1 |
Sanchakova, AV | 1 |
Minton, MJ | 1 |
Knight, RK | 1 |
Rubens, RD | 2 |
Hayward, JL | 1 |
Wilmanns, W | 2 |
Hartenstein, R | 1 |
Sauer, H | 1 |
Binsack, T | 1 |
Datta, SN | 1 |
Thomas, K | 1 |
Matthews, PN | 1 |
Gerritsen, RJ | 1 |
Teske, E | 1 |
Kraus, JS | 1 |
Rutteman, GR | 1 |
Culine, S | 1 |
Droz, JP | 1 |
Wahid, FS | 1 |
Fun, LC | 1 |
Keng, CS | 1 |
Ismail, F | 1 |
Laver, JH | 1 |
Mahmoud, H | 1 |
Pick, TE | 1 |
Hutchinson, RE | 1 |
Weinstein, HJ | 1 |
Schwenn, M | 1 |
Weitzman, S | 1 |
Murphy, SB | 1 |
Ochoa, S | 1 |
Shuster, JJ | 1 |
Yokobayashi, T | 1 |
Nakajima, T | 1 |
Sutcliffe, SB | 1 |
Wrigley, PF | 2 |
Stansfeld, AG | 1 |
Malpas, JS | 1 |
Umsawasdi, T | 2 |
Chainuvati, T | 1 |
Hitanant, S | 1 |
Nilprabhassorn, P | 2 |
Viranuvatti, V | 1 |
Lister, TA | 1 |
Whitehouse, JM | 1 |
Beard, ME | 1 |
Paxton, A | 1 |
Brearley, RL | 1 |
Brown, L | 1 |
Johansson, S | 1 |
Kutti, J | 1 |
Olsson, LB | 1 |
Borisov, AI | 1 |
Gibbons, RP | 1 |
Johnson, DE | 1 |
Prout, GR | 1 |
Schmidt, JD | 1 |
Soloway, MS | 1 |
Loening, SA | 1 |
Chu, TM | 1 |
Gaeta, JF | 1 |
Saroff, J | 1 |
Wajsman, Z | 1 |
Slack, N | 1 |
Scott, WW | 1 |
Russell, JA | 2 |
Baker, JW | 2 |
Dady, PJ | 3 |
Ford, HT | 3 |
Gazet, JC | 3 |
McKinna, JC | 1 |
Nash, AG | 2 |
Powles, TJ | 4 |
McKinna, JA | 1 |
Wood, RA | 1 |
Cziráki, L | 2 |
OO, M | 2 |
Kaye, SB | 1 |
Ikram, H | 1 |
Hoshino, T | 1 |
Wilson, CB | 1 |
Leese, CL | 1 |
Bondy, PK | 1 |
Trapeznikov, NN | 1 |
Kupin, VI | 1 |
Radzikhovskaia, RM | 1 |
Kadagidze, ZG | 1 |
Qasim, MM | 1 |
Zhukovskaia, ES | 1 |
Gorbunova, VA | 1 |
Khvatova, NV | 1 |
Gilbert, HA | 1 |
Yettra, M | 1 |
Gordon, J | 1 |
Kagan, AR | 1 |
Hirano, M | 1 |
Okamoto, M | 1 |
Maruyama, F | 1 |
Ezaki, K | 1 |
Shimizu, K | 1 |
Ino, T | 1 |
Matsui, T | 1 |
Sobue, R | 1 |
Shinkai, K | 1 |
Miyazaki, H | 1 |
Kristensen, B | 1 |
Ejlertsen, B | 1 |
Holmegaard, SN | 1 |
Krarup-Hansen, A | 1 |
Transbøl, I | 1 |
Mouridsen, H | 1 |
Bennett, A | 1 |
Melhuish, PB | 1 |
Patel, S | 1 |
Randles, H | 1 |
Stamford, IF | 1 |
Kojima, T | 1 |
Hoshino, A | 1 |
Ohara, K | 1 |
Kamiya, O | 1 |
Nagata, K | 1 |
Ito, Y | 1 |
Kinoshita, T | 1 |
Sugiura, I | 1 |
Yamada, M | 1 |
Sato, H | 1 |
Mitchell, I | 1 |
Deshpande, N | 1 |
Millis, R | 1 |
Taylor, SG | 1 |
Keidan, SE | 1 |
Helson, L | 1 |
Wollner, N | 1 |
Murphy, ML | 1 |
Schwartz, MK | 1 |
Maas, B | 1 |
Ruhrmann, G | 1 |
Alferova, MS | 1 |
Izmailova, GE | 1 |
Sviatukhina, OV | 1 |
Starichkov, MS | 1 |
Magrath, IT | 1 |
Mugerwa, J | 1 |
Bailey, I | 1 |
Olweny, C | 1 |
Kiryabwire, Y | 1 |
Franke, HD | 1 |
Landbeck, G | 1 |
Timmermann, J | 1 |
Winkler, K | 1 |
Willoughby, ML | 1 |
Saikia, NK | 1 |
MacKie, RM | 1 |
McQueen, A | 1 |
Evans, DB | 1 |
Calne, RY | 1 |
Buckle, R | 1 |
Fairley, GH | 1 |
Freeman, JE | 1 |
Hermann, J | 1 |
Zintl, F | 1 |
Plenert, W | 1 |
Vishniakova, EG | 1 |
Gossart, R | 1 |
Kulakowski, S | 1 |
Achslogh, J | 1 |
Malherbe, A | 1 |
de Vaan, GA | 1 |
Marcar, JR | 1 |
Schretlen, ED | 1 |
Ishimori, S | 1 |
Spiers, AS | 1 |
Wendel, H | 1 |
Kochan, E | 1 |
Kröger, W | 1 |
Mitchell, AB | 1 |
Pinn, G | 1 |
Pegrum, GD | 1 |
Ryan, SJ | 1 |
Frank, RN | 1 |
Green, WR | 1 |
Szabolcsi, I | 1 |
Gáspár, P | 1 |
Komáromy, J | 1 |
Vogler, WR | 1 |
Furtado, VP | 1 |
Huguley, CM | 1 |
Bankl, H | 1 |
Geyer, G | 1 |
Jesserer, H | 1 |
Keibl, E | 1 |
Kucsko, L | 1 |
Kotzaurek, R | 1 |
Müller-Grotjan, H | 1 |
Liegl, O | 1 |
Clinical Trials (10)
Trial Overview
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
An Open Label Phase I/Randomised, Double Blind Phase II Study in Metastatic Castration Resistant Prostate Cancer of AZD5363 In Combination With Docetaxel and Prednisolone Chemotherapy (ProCAID)[NCT02121639] | Phase 1/Phase 2 | 160 participants (Actual) | Interventional | 2014-01-29 | Completed | ||
A Randomized Phase II Trial Comparing Biomarker Directed Therapy Versus Clinician's Choice of Enzalutamide or Docetaxel in Patients With Advanced Prostate Cancer Post Abiraterone[NCT04015622] | Phase 2 | 100 participants (Anticipated) | Interventional | 2020-10-07 | Recruiting | ||
A Randomized, Double-blind, Comparative Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Subjects With High-Risk, Metastatic Hormone-naive Prostate Cancer (mHNPC)[NCT01715285] | Phase 3 | 1,209 participants (Actual) | Interventional | 2013-02-12 | Completed | ||
An Open-label, Phase I/IIa Dose Escalation and Expansion Study to Determine the Safety and Clinical Activity of an Immune Priming Cell Therapy (INKmune) in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)[NCT06056791] | Phase 1/Phase 2 | 30 participants (Anticipated) | Interventional | 2023-11-30 | Not yet recruiting | ||
A Single-center, Phase II Neoadjuvant Study of Abiraterone Acetate in the Treatment of Intraductal Carcinoma of the Prostate[NCT04736108] | Phase 2 | 50 participants (Anticipated) | Interventional | 2021-05-31 | Not yet recruiting | ||
STAMPEDE: Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy: A Multi-Stage Multi-Arm Randomised Controlled Trial[NCT00268476] | Phase 2/Phase 3 | 11,992 participants (Actual) | Interventional | 2005-07-08 | Active, not recruiting | ||
A Phase III Randomized, Double-blind, Placebo-controlled Trial of Radium-223 Dichloride in Combination With Abiraterone Acetate and Prednisone/Prednisolone in the Treatment of Asymptomatic or Mildly Symptomatic Chemotherapy-naïve Subjects With Bone Predom[NCT02043678] | Phase 3 | 806 participants (Actual) | Interventional | 2014-03-30 | Active, not recruiting | ||
Multicentre, Single-arm, Open Label Clinical Trial Intended to Provide Early Access to Cabazitaxel in Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing Regimen and to Document Safety of Cabazitaxel [NCT01254279] | Phase 3 | 984 participants (Actual) | Interventional | 2010-12-31 | Completed | ||
A Phase II Study of JNJ-212082 (Abiraterone Acetate) in Metastatic Castration Resistant Prostate Cancer Patients Who Are Chemotherapy-Naïve[NCT01756638] | Phase 2 | 48 participants (Actual) | Interventional | 2012-06-06 | Completed | ||
A Phase II Study of JNJ-212082 (Abiraterone Acetate) in Metastatic Castration-Resistant Prostate Cancer Patients Who Have Received Docetaxel-based Chemotherapy[NCT01795703] | Phase 2 | 47 participants (Actual) | Interventional | 2012-06-30 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Trial Outcomes
Overall Survival (OS)
Overall survival was defined as the time from randomization to date of death from any cause. (NCT01715285)
Timeframe: Up to 66 months
Intervention | months (Median) |
---|---|
Abiraterone Acetate+Prednisone+ADT | 53.32 |
Placebo + ADT | 36.53 |
Radiographic Progression-Free Survival (PFS)
Radiographic PFS was defined as the time (in months) interval from randomization to the first date of radiographic progression or death. Radiographic progression included progression by bone scan (according to modified Prostate Cancer Working Group 2 [PCWG2] criteria), defined as at least 2 new lesions on bone scan and progression of soft tissue lesions by computed tomography (CT) or magnetic resonance imaging (MRI) (according to Response Evaluation Criteria in Solid Tumors [RECIST] 1.1 criteria). As per the RECIST 1.1 guideline, progression requires a 20 percent (%) increase in the sum of diameters of all target lesions and a minimum absolute increase of 5 millimeter (mm) in the sum as compared to nadir sum of diameter. (NCT01715285)
Timeframe: Up to 44 months
Intervention | Months (Median) |
---|---|
Abiraterone Acetate+Prednisone+ADT | 33.02 |
Placebo + ADT | 14.78 |
Time to Initiation of Chemotherapy
Time to initiation of chemotherapy was defined as the time (in months) interval from the date of randomization to the date of initiation of cytotoxic chemotherapy for prostate cancer. (NCT01715285)
Timeframe: Up to 66 months
Intervention | months (Median) |
---|---|
Abiraterone Acetate+Prednisone+ADT | NA |
Placebo + ADT | 57.59 |
Time to Pain Progression
"Time to pain progression was defined as the time (in months) interval from randomization to the first date a participant experienced a greater than or equal to (>=) 30 percent (%) increase in Brief Pain Inventory-Short Form (BPI-SF) from baseline in the BPI-SF worst pain intensity (Item 3) observed at 2 consecutive evaluations (>=4) weeks apart. BPI-SF was an 11-item questionnaire, designed to assess severity and impact of pain on daily functions. Total score ranged from 0 to 10 with 0 representing no pain and 10 representing pain as bad as you can imagine." (NCT01715285)
Timeframe: Up to 66 months
Intervention | Months (Median) |
---|---|
Abiraterone Acetate+Prednisone+ADT | 47.41 |
Placebo + ADT | 16.62 |
Time to Prostate-Specific Antigen (PSA) Progression
Time to PSA progression was defined as the time (in months) interval from the date of randomization to the date of PSA progression, according to PCWG2 criteria. PCWG2 defines PSA progression as the date that a 25 percent (%) or greater increase and an absolute increase of 2 nanogram per milliliter (ng/mL) or more from the nadir is documented, which is confirmed by a second value obtained 3 or more weeks later. (NCT01715285)
Timeframe: Up to 66 months
Intervention | Months (Median) |
---|---|
Abiraterone Acetate+Prednisone+ADT | 33.31 |
Placebo + ADT | 7.43 |
Time to Skeletal-Related Event
Time to skeletal-related event was defined as the earliest of the following: clinical or pathological fracture, spinal cord compression, palliative radiation to bone, or surgery to bone. (NCT01715285)
Timeframe: Up to 66 months
Intervention | months (Median) |
---|---|
Abiraterone Acetate+Prednisone+ADT | NA |
Placebo + ADT | NA |
Time to Subsequent Therapy for Prostate Cancer
Time to subsequent therapy was defined as the time (in months) interval from the date of randomization to the date of initiation of subsequent therapy for prostate cancer. (NCT01715285)
Timeframe: Up to 66 months
Intervention | Months (Median) |
---|---|
Abiraterone Acetate+Prednisone+ADT | 54.87 |
Placebo + ADT | 21.22 |
Number of Participants With Any Treatment-emergent Additional Primary Malignancies
Treatment-emergent additional primary malignancies were adverse events identified as additional primary malignancies that occurred after start of study treatment until the end of the treatment period. (NCT02043678)
Timeframe: From start of study treatment until 4 weeks after last study treatment, up to 65 months
Intervention | Participants (Count of Participants) |
---|---|
Radium-223 Dichloride + Abi/Pred | 26 |
Placebo + Abi/Pred | 25 |
Number of Participants With Treatment-emergent Bone Fractures
Treatment-emergent fractures were adverse events identified as fractures that occurred after start of study treatment until the end of the treatment period. All bone fractures and bone-associated events (e.g., osteoporosis) were reported as either AEs, or SAEs if the criteria of SAE were met, regardless of the investigator's causality assessment. (NCT02043678)
Timeframe: From start of study treatment until 4 weeks after last study treatment, up to 65 months
Intervention | Participants (Count of Participants) |
---|---|
Radium-223 Dichloride + Abi/Pred | 107 |
Placebo + Abi/Pred | 49 |
Overall Survival (OS)
OS was defined as the time (months) from the date of randomization to the date of death due to any cause. Subjects alive at the survival cut-off date were censored at the last date known to be alive. (NCT02043678)
Timeframe: From randomization until death from any cause, up to 67 months
Intervention | Months (Median) |
---|---|
Radium-223 Dichloride + Abi/Pred | 30.1 |
Placebo + Abi/Pred | 34.8 |
Radiological Progression Free Survival (rPFS)
rPFS was defined as the time (months) from the date of randomization to the date of confirmed radiological progression or death (if death occurred before progression) based on independent assessment. (NCT02043678)
Timeframe: From randomization until the date of confirmed radiological progression or death, up to 47 months
Intervention | Months (Median) |
---|---|
Radium-223 Dichloride + Abi/Pred | 11.2 |
Placebo + Abi/Pred | 12.4 |
Symptomatic Skeletal Event Free Survival (SSE-FS)
SSE-FS was defined as time (months) from randomization to the earliest of onset date of skeletal symptoms treated with external beam radiotherapy (EBRT), onset date of pathological bone fracture, onset date of spinal cord compression, procedure date of tumor-related orthopedic surgery, or death from any cause. Subjects who died without prior SSE and ≥ 13 weeks after the last SSE assessment are censored at the last SSE assessment date. Subjects alive at the survival cut-off date are censored at the last date known to be alive. Subjects with multiple events are only counted for the category in which the first event occurred. If multiple SSE (component events) occur on the same date for 1 subject, the subject is only counted into 1 category in the order of: spinal cord compression > bone fracture > orthopedic surgery > EBRT. (NCT02043678)
Timeframe: From randomization until first onset of on-study symptomatic skeletal event (SSE) or death, up to 47 months
Intervention | Months (Median) |
---|---|
Radium-223 Dichloride + Abi/Pred | 22.3 |
Placebo + Abi/Pred | 26.0 |
Time to Cytotoxic Chemotherapy
Time to cytotoxic chemotherapy is time (months) from randomization to the earliest date of the first cytotoxic chemotherapy. Participants who have not started cytotoxic chemotherapy during the study were censored at the last assessment date. (NCT02043678)
Timeframe: From randomization until the date of first cytotoxic chemotherapy, up to 47 months
Intervention | Months (Median) |
---|---|
Radium-223 Dichloride + Abi/Pred | 29.5 |
Placebo + Abi/Pred | 28.5 |
Time to Opiate Use for Cancer Pain
Time to opiate use for cancer pain was defined as the interval from the date of randomization to the date of opiate use. (NCT02043678)
Timeframe: From randomization until the date of opiate use, up to 47 months
Intervention | Months (Median) |
---|---|
Radium-223 Dichloride + Abi/Pred | 19.0 |
Placebo + Abi/Pred | 22.6 |
Time to Pain Progression
Time to pain progression was defined as the interval from randomization to the first date a subject experienced pain progression, assessed by BPI-SF (see Baseline Characteristics) and defined as: an increase of 2 or more points in the average worst pain score (WPS) from baseline observed at 2 consecutive evaluations >= 4 weeks apart or initiation of short- or long-acting opioid use for pain for subjects with WPS 0 at baseline; an increase of 2 or more points in the average WPS from baseline observed at 2 consecutive evaluations ≥ 4 weeks apart and an average WPS of ≥ 4 OR initiation of short- or long-acting opioid use for pain for subjects with WPS 1 to 3 at baseline. Subjects without pain progression at the end of study are censored at the last date known to have not progressed: the last evaluation date for pain scores or last visit when recorded opiate use, whichever is last. Subjects with no on-study assessment or no baseline assessment are censored at the date of randomization. (NCT02043678)
Timeframe: From randomization until the date of pain progression based on pain score, up to 47 months
Intervention | Months (Median) |
---|---|
Radium-223 Dichloride + Abi/Pred | 14.4 |
Placebo + Abi/Pred | 18.7 |
Number of Participants With Any Study Drug-related Post-treatment Adverse Events Per Maximum Intensity
"An adverse event (AE) was any untoward medical occurrence (i.e., any unfavorable and unintended sign [including abnormal laboratory findings], symptom or disease) in a participant in the study. Any bleeding event occurring during the study was not documented as an AE because this event was planned to be captured in the assessment of efficacy. AEs that started after the treatment period were defined as post-treatment AEs. Drug-related AEs were those with reasonable causal relationship to the study treatment decided by the investigators." (NCT02043678)
Timeframe: After the treatment period, up to 46 months
Intervention | Participants (Count of Participants) | |||
---|---|---|---|---|
Grade 1 | Grade 2 | Grade 3 | Grade 4 | |
Placebo + Abi/Pred | 3 | 3 | 3 | 0 |
Radium-223 Dichloride + Abi/Pred | 3 | 9 | 5 | 1 |
Number of Participants With Post-treatment Adverse Events
"An adverse event (AE) was any untoward medical occurrence (i.e., any unfavorable and unintended sign [including abnormal laboratory findings], symptom or disease) in a participant in the study. Any bleeding event occurring during the study was not documented as an AE because this event was planned to be captured in the assessment of efficacy. AEs that started after the treatment period were defined as post-treatment AEs. Drug-related AEs were those with reasonable causal relationship to the study treatment decided by the investigators." (NCT02043678)
Timeframe: After the treatment period, up to 46 months
Intervention | Participants (Count of Participants) | |||
---|---|---|---|---|
Any events | Any drug-related events | Any chemotherapy-related events | Any additional primary malignancies | |
Placebo + Abi/Pred | 133 | 9 | 34 | 7 |
Radium-223 Dichloride + Abi/Pred | 138 | 18 | 31 | 6 |
Number of Participants With Post-treatment Bone Fractures
Post-treatment fractures were adverse events identified as fractures that occured after the end of the treatment period until participant died, was lost to follow-up, withdrew informed consent, actively objected to collection of further data, or was transitioned to the extended safety follow-up study. All bone fractures and bone-associated events (e.g., osteoporosis), were reported as either AEs, or SAEs if the criteria of SAE were met, regardless of the investigator's causality assessment. (NCT02043678)
Timeframe: After the treatment period, up to 46 months
Intervention | Participants (Count of Participants) | ||||||
---|---|---|---|---|---|---|---|
Lumbar vertebral fracture | Rib fracture | Spinal compression fracture | Thoracic vertebral fracture | Traumatic fracture | Osteoporotic fracture | Pathological fracture | |
Placebo + Abi/Pred | 1 | 1 | 1 | 1 | 2 | 0 | 13 |
Radium-223 Dichloride + Abi/Pred | 0 | 0 | 0 | 0 | 6 | 6 | 12 |
Number of Participants With Post-treatment Chemotherapy-related Blood and Lymphatic System Disorders
Post-treatment blood and lymphatic system disorders were adverse events identified as blood and lymphatic system disorders that occurred after the end of the treatment period until participant died, was lost to follow-up, withdrew informed consent, actively objected to collection of further data, or was transitioned to the extended safety follow-up study. (NCT02043678)
Timeframe: After the treatment period, up to 46 months
Intervention | Participants (Count of Participants) | ||||||
---|---|---|---|---|---|---|---|
Anaemia | Bone marrow failure | Febrile neutropenia | Leukopenia | Neutropenia | Pancytopenia | Thrombocytopenia | |
Placebo + Abi/Pred | 4 | 0 | 8 | 0 | 3 | 1 | 2 |
Radium-223 Dichloride + Abi/Pred | 5 | 1 | 5 | 1 | 8 | 0 | 2 |
Number of Participants With Treatment-emergent Adverse Events
"An adverse event (AE) was any untoward medical occurrence (i.e., any unfavorable and unintended sign [including abnormal laboratory findings], symptom or disease) in a participant in the study. A serious adverse event (SAE) was any untoward medical occurrence that at any dose was resulting in death, was lifethreatening, requires hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity. AEs or SAEs occurring after start of study treatment until the end of the treatment period were defined as treatment-emergent AEs (TEAEs) or serious TEAEs. Drug-related TEAEs or serious TEAEs were those with reasonable causal relationship to the study treatment decided by the investigators." (NCT02043678)
Timeframe: From start of study treatment until the end of the treatment period, up to 65 months
Intervention | Participants (Count of Participants) | |||||
---|---|---|---|---|---|---|
Any TEAE | Any drug-related TEAE | Radium-223/Placebo-related TEAE | Any serious TEAE | Any drug-related serious TEAE | Radium-223/Placebo-related serious TEAE | |
Placebo + Abi/Pred | 387 | 271 | 92 | 172 | 29 | 7 |
Radium-223 Dichloride + Abi/Pred | 382 | 265 | 92 | 175 | 32 | 11 |
Number of Subjects With Radium-223/Placebo-related Treatment-emergent Adverse Events Per Maximum Intensity
"An adverse event (AE) was any untoward medical occurrence (i.e., any unfavorable and unintended sign [including abnormal laboratory findings], symptom or disease) in a participant in the study. A serious adverse event (SAE) was any untoward medical occurrence that at any dose was resulting in death, was lifethreatening, requires hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity. AEs or SAEs occurring after start of study treatment until the end of the treatment period were defined as treatment-emergent AEs (TEAEs) or serious TEAEs. Radium-223/placebo-related TEAEs or serious TEAEs were those with reasonable causal relationship to radium-223 or placebo decided by the investigators." (NCT02043678)
Timeframe: From start of study treatment until the end of the treatment period, up to 65 months
Intervention | Participants (Count of Participants) | ||||||
---|---|---|---|---|---|---|---|
TEAE - Grade 1 | TEAE - Grade 2 | TEAE - Grade 3 | TEAE - Grade 4 | Serious TEAE - Grade 2 | Serious TEAE - Grade 3 | Serious TEAE - Grade 4 | |
Placebo + Abi/Pred | 53 | 24 | 13 | 2 | 0 | 5 | 2 |
Radium-223 Dichloride + Abi/Pred | 44 | 28 | 19 | 1 | 3 | 8 | 0 |
Reviews
10 reviews available for prednisolone and Neoplasm Metastasis
Article | Year |
---|---|
Role of second-line systemic treatment post-docetaxel in metastatic castrate resistant prostate cancer- current strategies and future directions.
Topics: Androstenes; Androstenols; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cl | 2011 |
Novel therapeutic strategies for metastatic prostate cancer in the post-docetaxel setting.
Topics: Androstenes; Androstenols; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Ca | 2011 |
SELECTION AND TREATMENT OF PATIENTS WITH ADVANCED BREAST CANCER.
Topics: Adrenalectomy; Androgens; Breast; Breast Neoplasms; Cortisone; Estrogens; Female; Humans; Hypophysec | 1964 |
The changing pattern of management for hormone-refractory, metastatic prostate cancer.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocol | 2006 |
A systematic review of the effectiveness of docetaxel and mitoxantrone for the treatment of metastatic hormone-refractory prostate cancer.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Res | 2006 |
Chemotherapy in advanced androgen-independent prostate cancer 1990-1999: a decade of progress?
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemothe | 2000 |
Breast carcinoma presenting as immune thrombocytopenic purpura.
Topics: Adult; Autoimmune Diseases; Breast Neoplasms; Carcinoma, Ductal, Breast; Female; Humans; Immunosuppr | 2001 |
Review of basic concepts of cell kinetics as applied to brain tumors.
Topics: Alkylating Agents; Anti-Bacterial Agents; Antimetabolites; Astrocytoma; Brain; Brain Neoplasms; Cell | 1975 |
Ectopic PTH syndrome, pseudohyperparathyroidism; hypercalcaemia of malignancy.
Topics: Adenocarcinoma; Adenoma; Alkaline Phosphatase; Bone and Bones; Bone Resorption; Calcium; Carcinoma; | 1974 |
[Diagnosis and therapy of acute lymphatic leukemia in childhood].
Topics: Asparaginase; Child; Cyclophosphamide; Cytarabine; Daunorubicin; Doxorubicin; Humans; Leukemia, Lymp | 1974 |
Trials
18 trials available for prednisolone and Neoplasm Metastasis
Article | Year |
---|---|
Efficacy and safety of abiraterone acetate plus prednisolone in patients with early metastatic castration-resistant prostate cancer who failed first-line androgen-deprivation therapy: a single-arm, phase 4 study.
Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Androgens; Antineoplastic Combined Chemotherapy Protoc | 2021 |
Pan-AKT Inhibitor Capivasertib With Docetaxel and Prednisolone in Metastatic Castration-Resistant Prostate Cancer: A Randomized, Placebo-Controlled Phase II Trial (ProCAID).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Doceta | 2021 |
Population Pharmacokinetics of Ipatasertib and Its Metabolite in Cancer Patients.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Antineoplastic Comb | 2021 |
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.
Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined C | 2017 |
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.
Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined C | 2017 |
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.
Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined C | 2017 |
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.
Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined C | 2017 |
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.
Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined C | 2017 |
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.
Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined C | 2017 |
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.
Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined C | 2017 |
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.
Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined C | 2017 |
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.
Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined C | 2017 |
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.
Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined C | 2017 |
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.
Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined C | 2017 |
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.
Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined C | 2017 |
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.
Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined C | 2017 |
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.
Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined C | 2017 |
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.
Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined C | 2017 |
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.
Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined C | 2017 |
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.
Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined C | 2017 |
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.
Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined C | 2017 |
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.
Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined C | 2017 |
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.
Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined C | 2017 |
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.
Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined C | 2017 |
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.
Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined C | 2017 |
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.
Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined C | 2017 |
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.
Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined C | 2017 |
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.
Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined C | 2017 |
Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Abiraterone Acetate; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone N | 2019 |
Cabazitaxel for metastatic castration-resistant prostate cancer: safety data from the Spanish expanded access program.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Middle Aged; Neoplasm | 2014 |
A phase 2 trial of abiraterone acetate in Japanese men with metastatic castration-resistant prostate cancer and without prior chemotherapy (JPN-201 study).
Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Prot | 2014 |
A phase 2 study of abiraterone acetate in Japanese men with metastatic castration-resistant prostate cancer who had received docetaxel-based chemotherapy.
Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Hum | 2014 |
Prolonged treatment with three-weekly docetaxel plus daily prednisolone for metastatic castration-resistant prostate cancer: a multicenter, phase II, open-label, non-comparative, extension study in Japan.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Administration Schedule; Drug- | 2013 |
Chemotherapy in metastatic, hormone refractory prostatic cancer using chlorambucil in combination with prednisolone versus conjugate, prednimustine (Leo 1031).
Topics: Aged; Antineoplastic Agents; Chlorambucil; Clinical Trials as Topic; Drug Therapy, Combination; Huma | 1981 |
Intermittent high-dose cyclophosphamide with and without prednisolone: a study of the relationships between toxicity, response and survival in metastatic lung cancer.
Topics: Adult; Aged; Clinical Trials as Topic; Cyclophosphamide; Drug Administration Schedule; Drug Therapy, | 1982 |
Is prednisolone as good as flutamide in hormone refractory metastatic carcinoma of the prostate?
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flutamide; Humans; M | 1997 |
Results of a randomized phase III trial in children and adolescents with advanced stage diffuse large cell non Hodgkin's lymphoma: a Pediatric Oncology Group study.
Topics: Adolescent; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Child; Cyclophosphamide; D | 2001 |
[Combined drug treatment of far-advanced forms of breast cancer].
Topics: Antineoplastic Agents; Breast Neoplasms; Castration; Clinical Trials as Topic; Cyclophosphamide; Dru | 1978 |
Response of metastatic breast cancer to combination chemotherapy according to site.
Topics: Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Female; Fluorouracil; Hu | 1977 |
Prednisolone in the treatment of severe malignant hypercalcaemia in metastatic breast cancer: a randomized study.
Topics: Administration, Oral; Adult; Aged; Breast Neoplasms; Calcium; Female; Fluid Therapy; Furosemide; Hum | 1992 |
The effects of multiple combination chemotherapy with vincristine, cyclophosphamide (Endoxan), methotrexate, 5-fluorouracil, adriamycin and prednisolone (VEMFAH) for advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as To | 1985 |
Other Studies
83 other studies available for prednisolone and Neoplasm Metastasis
Article | Year |
---|---|
Treatment options for patients with prostate cancer who develop metastatic disease after hormonal therapy.
Topics: Abiraterone Acetate; Absorptiometry, Photon; Aged; Antineoplastic Combined Chemotherapy Protocols; B | 2019 |
Aggressive Inflammatory Myofibroblastic Tumor without Anaplastic Lymphoma Kinase Gene Rearrangement in the Rectum with Liver Metastasis.
Topics: Aged, 80 and over; Anti-Inflammatory Agents; Fatal Outcome; Humans; Liver Neoplasms; Lymphoma; Male; | 2020 |
An ERG Gene Analysis in Two Cases with Metastatic Castration-resistant Prostate Cancer in Which Abiraterone Demonstrated Long-term Efficacy.
Topics: Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Humans; Male; Middle Aged; Neopla | 2020 |
Commentary on: Abiraterone Plus Prednisolone in Metastatic, Castration-sensitive Prostate Cancer.
Topics: Abiraterone Acetate; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Castration; Diseas | 2017 |
Real-world uptake, safety profile and outcomes of docetaxel in newly diagnosed metastatic prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents; Antineoplastic Combined Chemot | 2018 |
Abiraterone acetate + prednisolone treatment beyond prostate specific antigen and radiographic progression in metastatic castration-resistant prostate cancer patients.
Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Alkaline Phosphatase; Antineoplastic Combined Chemothe | 2018 |
Stevens-Johnson syndrome/toxic epidermal necrolysis overlap in a NSCLC patient treated with afatinib.
Topics: Adenocarcinoma; Afatinib; Aftercare; Antineoplastic Agents; Biopsy; Female; Humans; Lung Neoplasms; | 2018 |
Sweet syndrome associated with ipilimumab in a patient with metastatic melanoma.
Topics: Aged; Antineoplastic Agents, Immunological; Betamethasone; Glucocorticoids; Humans; Ipilimumab; Male | 2018 |
Stevens-Johnson syndrome induced by sorafenib for metastatic renal cell carcinoma.
Topics: Aged; Betamethasone; Carcinoma, Renal Cell; Fatal Outcome; Humans; Kidney Neoplasms; Male; Neoplasm | 2013 |
Safety of cabazitaxel in senior adults with metastatic castration-resistant prostate cancer: results of the European compassionate-use programme.
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Compassionate Use T | 2014 |
Effectiveness and safety of cabazitaxel plus prednisolone chemotherapy for metastatic castration-resistant prostatic carcinoma: data on Korean patients obtained by the cabazitaxel compassionate-use program.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocol | 2014 |
Translating Clinical Evidence-Based Medicine into the Real World: Single-Center Experience with Cabazitaxel in Metastatic Prostate Cancer Patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Evidence-Based Med | 2016 |
Co-introduction of a steroid with docetaxel chemotherapy for metastatic castration-resistant prostate cancer affects PSA flare.
Topics: Aged; Antineoplastic Agents; Dexamethasone; Docetaxel; Drug Therapy, Combination; Glucocorticoids; H | 2016 |
Idiopathic fibrosing mediastinitis mimicking nodal metastasis from breast cancer.
Topics: Biopsy; Breast Neoplasms; Diagnosis, Differential; Female; Fluorodeoxyglucose F18; Glucocorticoids; | 2017 |
Diffuse edema suggestive of cytokine release syndrome in a metastatic lung carcinoma patient treated with pembrolizumab.
Topics: Anemia; Antibodies, Monoclonal, Humanized; Carcinoma, Squamous Cell; Cytokines; Drug-Related Side Ef | 2017 |
Neurological picture. Vertebral sarcoidosis mimicking metastases.
Topics: Anti-Inflammatory Agents; Biopsy; Diagnosis, Differential; Female; Humans; Immunosuppressive Agents; | 2011 |
[Complete response achieved in a case of gastric gastrointestinal stromal tumor by administration of imatinib mesilate with concurrent relatively high-dose steroid therapy to control side effects].
Topics: Benzamides; Drug Eruptions; Drug Therapy, Combination; Gastrointestinal Stromal Tumors; Humans; Imat | 2010 |
Treatment of radiation-induced hemorrhagic gastritis with prednisolone: a case report.
Topics: Carcinoma, Hepatocellular; Endoscopy; Gastritis; Gastrointestinal Hemorrhage; Hemostasis; Humans; Li | 2012 |
Echocardiographic recognition of cardiac leukemic tumors in a child successfully treated with chemotherapy.
Topics: Antineoplastic Agents; Asparaginase; Child; Diagnosis, Differential; Echocardiography; Heart Neoplas | 2003 |
Nitrogen mustard in the palliation of lung and metastatic lung cancer.
Topics: Adenocarcinoma; Carcinoma; Carcinoma, Squamous Cell; Humans; Lung Neoplasms; Mechlorethamine; Neopla | 1962 |
[ENZYME DETERMINATIONS IN THE SERUM IN LIVER DISEASES. FUNCTION PATTERNS AS A MEANS OF DIAGNOSIS].
Topics: Alanine Transaminase; Alkaline Phosphatase; Aspartate Aminotransferases; Bilirubin; Cholecystitis; C | 1963 |
[SURGERY ON THE PITUITARY GLAND AND ANESTHESIA].
Topics: Adrenocorticotropic Hormone; Anesthesia; Breast Neoplasms; Cortisone; Desoxycorticosterone; Gonadotr | 1963 |
CHLORAMBUCIL-PREDNISOLONE THERAPY FOR DISSEMINATED BREAST CARCINOMA.
Topics: Adrenal Cortex Hormones; Alkylating Agents; Antineoplastic Agents; Biomedical Research; Breast Neopl | 1964 |
DEVELOPMENT OF SQUAMOUS CELL CARCINOMA IN BENIGN MUCOUS MEMBRANE PEMPHIGUS: REPORT OF A CASE.
Topics: Brain Neoplasms; Carcinoma, Squamous Cell; Humans; Mouth Diseases; Mouth Mucosa; Neoplasm Metastasis | 1964 |
USE OF GLUCOCORTICOIDS IN THE PALLIATIVE TREATMENT OF METASTATIC BRAIN TUMORS.
Topics: Brain Neoplasms; Dexamethasone; Drug Therapy; Geriatrics; Glucocorticoids; Humans; Hydrocortisone; M | 1965 |
HYPERCALCEMIA OF BREAST CANCER; MANAGEMENT WITH CORTICOSTEROIDS.
Topics: Adrenal Cortex Hormones; Breast Neoplasms; Calcium; Carcinoma; Drug Therapy; Geriatrics; Humans; Hyp | 1965 |
Hypersensitivity pneumonitis associated with the use of trofosfamide.
Topics: Administration, Oral; Aged; Alveolitis, Extrinsic Allergic; Antineoplastic Combined Chemotherapy Pro | 2004 |
Concomitant deposition of aluminum and iron in bone marrow trabeculae.
Topics: Aluminum; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cyclophosphamide; Doxorubicin | 2006 |
Severe lung and skin toxicity during treatment with gemcitabine and erlotinib for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Erlotinib Hydrochlori | 2007 |
Technic and diagnostic value of the transparietohepatic cholangiography.
Topics: Analgesics; Bile Duct Neoplasms; Cholangiography; Cholelithiasis; Cysts; Dexamethasone; Gallbladder | 1967 |
[Diagnosis and therapy of micromolecular plasmocytomas -- a case report].
Topics: Bence Jones Protein; Humans; Immunoglobulin kappa-Chains; Lumbar Vertebrae; Male; Melphalan; Middle | 1980 |
VAP-cyclo: a short intensive regimen of chemotherapy for advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 1982 |
Cyclophosphamide-prednisolone therapy in advanced prostatic carcinoma.
Topics: Acid Phosphatase; Cyclophosphamide; Drug Therapy, Combination; Humans; Male; Neoplasm Metastasis; Pr | 1980 |
[Use of "split" courses of combination chemotherapy in breast cancer].
Topics: Breast Neoplasms; Cyclophosphamide; Drug Evaluation; Drug Therapy, Combination; Female; Fluorouracil | 1981 |
Corticosteroids for elderly patients with breast cancer.
Topics: Aged; Androgens; Breast Neoplasms; Cortisone; Estrogens; Female; Humans; Neoplasm Metastasis; Predni | 1981 |
[Chemotherapy of breast cancer].
Topics: Adult; Breast Neoplasms; Cyclophosphamide; Female; Fluorouracil; Humans; Mastectomy; Methotrexate; N | 1981 |
Multi-agent chemotherapy for mast cell tumours in the dog.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dog Diseases; Dogs; Doxor | 1998 |
Chemotherapy in the treatment of osteogenic sarcoma of the maxilla (case report).
Topics: Alkaline Phosphatase; Bleomycin; Cyclophosphamide; Doxorubicin; Female; Humans; Maxillary Neoplasms; | 1978 |
Adriamycin, bleomycin, vinblastine and imidazole carboxamide (ABVD) therapy for advanced Hodgkin's disease resistant to mustine, vinblastine, procarbazine and prednisolone (MVPP).
Topics: Adolescent; Adult; Alopecia; Antineoplastic Agents; Bleomycin; Child; Doxorubicin; Drug Administrati | 1979 |
Combination chemotherapy with 5--fluorouracil, amethopterin (methotrexate) and prednisolone (FAP protocol) in the therapy of cholangiocarcinoma.
Topics: Adenoma, Bile Duct; Drug Therapy, Combination; Fluorouracil; Humans; Liver Neoplasms; Male; Methotre | 1976 |
Early central nervous system involvement in adults with acute non-myelogenous leukaemia.
Topics: Adolescent; Adult; Asparaginase; Central Nervous System Diseases; Humans; Leukemia, Lymphoid; Middle | 1977 |
Rapid platelet consumption in a case of metastatic osteogenic sarcoma of the breast.
Topics: Aged; Blood Platelets; Blood Transfusion; Breast Neoplasms; Cell Survival; Female; Heart Neoplasms; | 1978 |
The use of estramustine and prednimustine versus prednimustine alone in advanced metastatic prostatic cancer patients who have received prior irradiation.
Topics: Chlorambucil; Drug Therapy, Combination; Estramustine; Humans; Male; Nausea; Neoplasm Metastasis; Ni | 1979 |
Combination chemotherapy of metastatic breast cancer with vincristine adriamycin and prednisolone.
Topics: Aged; Bone Marrow; Breast Neoplasms; Doxorubicin; Drug Therapy, Combination; Female; Humans; Middle | 1978 |
If I had Hodgkin's disease.
Topics: Drug Therapy, Combination; Hodgkin Disease; Humans; Neoplasm Metastasis; Neoplasm Staging; Nitrogen | 1978 |
Combination chemotherapy with cyclophosphamide (NSC-26 271), methotrexate (NSC-740), and prednisolone (NSC-9 900) (CMP protocol), for metastatic breast cancer.
Topics: Adult; Aged; Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Female; Humans; Methotre | 1978 |
Combination therapy in metastatic breast cancer.
Topics: Adult; Aged; Breast Neoplasms; Chlorambucil; Drug Therapy, Combination; Female; Humans; Middle Aged; | 1977 |
Combination chemotherapy for thrombocytopenia with bone marrow metastases from breast cancer.
Topics: Adult; Bone Marrow Diseases; Breast Neoplasms; Doxorubicin; Drug Therapy, Combination; Female; Human | 1977 |
[Combined leukeran-prednisolone therapy in metastasizing breast cancer].
Topics: Adenocarcinoma; Adult; Aged; Breast Neoplasms; Chlorambucil; Drug Therapy, Combination; Female; Huma | 1977 |
Acute cardiac pain and electrocardiographic changes following cytotoxic treatment for metastatic carcinoma.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Breast Neoplasms; Coronary Disease; Cyclophosphamide; | 1976 |
Hydroxyproline excretion in patients with breast cancer and response to treatment.
Topics: Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Calcium; Ethinyl Estradiol; Female; Humans; | 1975 |
[Evaluation of the immunological reactivity of melanoma patients using the rosette formation test].
Topics: Cyclophosphamide; Drug Therapy, Combination; Female; Humans; Immune Adherence Reaction; Immunosuppre | 1975 |
Leucoerythroblastic anaemia in carcinoma of ovary.
Topics: Anemia, Myelophthisic; Bone Marrow Examination; Cystadenocarcinoma; Female; Humans; Middle Aged; Neo | 1975 |
[Blood coagulation system in oncological patients treated with rubomycin, adriamycin and carminomycin].
Topics: Antibiotics, Antineoplastic; Blood Coagulation; Blood Coagulation Tests; Blood Platelets; Carubicin; | 1976 |
On long-term survivals in non-Hodgkin's lymphoma with 'gentle' treatment.
Topics: Adult; Aged; Child; Chlorambucil; Female; Follow-Up Studies; Humans; Lymph Nodes; Lymphoma; Male; Mi | 1976 |
Alternating non-cross-resistant chemotherapy for non-Hodgkin's lymphoma of intermediate-grade and high-grade malignancy. A pilot study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Cyclo | 1992 |
Cancer in mice: effects of prednisolone or mepacrine alone and with cytotoxic drugs.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Female; Male; Mammary Neoplasms, Experimental; Melphalan; Met | 1987 |
Deoxyribonucleic acid (DNA) content of primary carcinoma and response to endocrine or cytotoxic drug therapies in patients with advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Castration; Combined Modality Ther | 1985 |
Common medical problems in disseminated cancer.
Topics: Androgens; Brain Neoplasms; Chlorothiazide; Dactinomycin; Estrogens; Humans; Hypercalcemia; Lymphede | 1970 |
Paraplegia in childhood malignant disease.
Topics: Adolescent; Child; Child, Preschool; Cyclophosphamide; Dactinomycin; Female; Humans; Infant; Leukemi | 1967 |
Chemotherapy of breast cancer by regional intra-arterial infusion.
Topics: Adult; Aged; Antineoplastic Agents; Brachial Artery; Breast Neoplasms; Carotid Arteries; Cyclophosph | 1970 |
Metastatic adrenal cortical carcinoma: biochemical changes accompanying clinical regression during therapy with o,p'-DDD.
Topics: 17-Hydroxycorticosteroids; 17-Ketosteroids; Abdominal Neoplasms; Acetates; Adrenal Gland Neoplasms; | 1971 |
[Adriamycin in the therapy of child leukemias and tumors].
Topics: Acute Disease; Adolescent; Doxorubicin; Humans; Leukemia; Lung Neoplasms; Lymphoma, Non-Hodgkin; Neo | 1973 |
[Late results of breast cancer treatment].
Topics: Adenocarcinoma; Adenocarcinoma, Scirrhous; Adult; Breast Neoplasms; Carcinoma; Carcinoma, Intraducta | 1973 |
[Complex treatment with radiation action on the hypophysis in generalized breast cancer].
Topics: Breast Neoplasms; Female; Follow-Up Studies; Humans; Male; Neoplasm Metastasis; Pituitary Irradiatio | 1974 |
Intracerebral Burkitt's lymphoma: pathology, clinical features and treatment.
Topics: Adolescent; Allopurinol; Brain Neoplasms; Burkitt Lymphoma; Child; Child, Preschool; Cyclophosphamid | 1974 |
[Indications for radiotherapy of acute leukemia in children with special reference to clinically non-manifest involvement of CNS].
Topics: Age Factors; Brain Neoplasms; Child; Cobalt Radioisotopes; Cyclophosphamide; Germany, West; Humans; | 1974 |
Blood and neoplastic diseases. Acute lymphoblastic leukaemia.
Topics: Arachnoid; Asparaginase; Brain Neoplasms; Cerebrospinal Fluid; Child; Cyclophosphamide; Daunorubicin | 1974 |
A case of bullous pemphigoid and figurate erythema in association with metastatic spread of carcinoma.
Topics: Adenocarcinoma; Alkaline Phosphatase; Eosinophils; Erythema; Fluorescent Antibody Technique; Hepatom | 1973 |
Renal transplantation in patients with carcinoma.
Topics: Adult; Angiography; Azathioprine; Cadaver; Female; Graft Rejection; Hematuria; Humans; Immunosuppres | 1974 |
Blood and neoplastic diseases. Treatment of the lymphomas.
Topics: Alopecia; Bone Marrow; Cyclophosphamide; Hodgkin Disease; Humans; Lymphoma; Lymphoma, Follicular; Ne | 1974 |
[Hormonal prevention of recurrence and metastasis in the complex treatment of breast cancer].
Topics: Adult; Aged; Androgens; Breast Neoplasms; Castration; Estrogens; Female; Humans; Mastectomy; Middle | 1968 |
[Hemangiopericytoma with metastases. Effect of prednisone treatment].
Topics: Brain Diseases; Buttocks; Child, Preschool; Cysts; Hemangiopericytoma; Humans; Infant; Infant, Newbo | 1971 |
Comparison of CNS-leukaemia in children with acute leukaemia, induced either with rubidomycin or L-asparaginase.
Topics: Asparaginase; Central Nervous System Diseases; Child; Child, Preschool; Daunorubicin; Drug Therapy, | 1971 |
[Metastic tumors of the brain].
Topics: Adolescent; Adult; Aged; Brain Neoplasms; Breast Neoplasms; Cerebral Angiography; Cerebral Ventricul | 1967 |
Cerebral metastases from carcinoma of the lung.
Topics: Aged; Betamethasone; Brain; Brain Neoplasms; Carcinoma; Carotid Arteries; Cerebral Ventriculography; | 1969 |
[Clinical aspects of malignant pleurisy].
Topics: Adult; Aged; Biopsy; Diagnosis, Differential; Female; Humans; Male; Mesothelioma; Middle Aged; Neopl | 1970 |
Pure red cell aplasia and carcinoma.
Topics: Adenocarcinoma; Aged; Anemia, Aplastic; Autopsy; Blood Transfusion; Bone Marrow Examination; Chromiu | 1971 |
Bilateral inflammatory pseudotumors of the ciliary body.
Topics: Administration, Topical; Anti-Inflammatory Agents; Atropine; Biopsy; Ciliary Body; Diagnosis, Differ | 1971 |
[Leucosarcomatosis with heart metastasis].
Topics: Adult; Anti-Bacterial Agents; Blood Transfusion; Bone Marrow Examination; Heart Neoplasms; Humans; L | 1967 |
Methotrexate for advanced cancer of the breast.
Topics: Adenocarcinoma; Adult; Aged; Androgens; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Met | 1968 |
[Hypercalcemic crisis and hypocalcemic tetany during treatment with sex hormones in a case of breast carcinoma with metastasis in the skeleton and parathyroid glands].
Topics: Blood Chemical Analysis; Blood Sedimentation; Bone Marrow Examination; Bone Neoplasms; Breast Neopla | 1966 |
[Cytostatic therapy of choroid membrane metastases].
Topics: Aged; Breast Neoplasms; Chlorambucil; Choroid Neoplasms; Cyclophosphamide; Female; Humans; Mastectom | 1966 |